Compound class:
Synthetic organic
Comment: TNG-462 (Tango Therapuetics) is a MTA-cooperative protein arginine methyltransferases 5 (PRMT5) inhibitor, that is proposed to treat methylthioadenosine phosphorylase (MTAP) deleted solid tumours. MTAP deficient cancer cells are unable to obtain adenine and methionine from the salvage pathway [1]. Adding inhibition of PRMT5 further decreases the viability of MTAP deficient cancer cells [2]. The chemical structure shown here was revealed during the First Time Disclosures session at the ACS meeting in September 2023, and we picked it up from Drug Hunter.
|
|
No information available. |
Summary of Clinical Use |
TNG-462 is in clinical development. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT05732831 | Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors | Phase 1/Phase 2 Interventional | Tango Therapeutics, Inc. |